Glioblastoma Multiforme Treatment Market Overview

In 2021, the market for treatments for glioblastoma multiforme was estimated to be worth US$ 1.5371 Billion. Between 2023 to 2032, it is anticipated to expand at a compound annual growth rate (CAGR) of 8.9%. The rising incidence of glioblastoma multiple, improved R&D, and favorable regulatory conditions are anticipated to propel market expansion. Over the projected period, a strong pipeline will be a major force in the glioblastoma multiple (GBM) therapy market. The market is anticipated to expand during the forecast period as a result of the rising incidence of brain malignancies.

Global Glioblastoma Multiforme Treatment Market Scope:

Treatment Analysis

Radiation therapy dominated the market in 2021 with a 38.3% revenue share thanks to its superior survival rates. For the first treatment or when paired with chemotherapy and surgery, radiation therapy is advised. It is quite effective and advised in the case of brain tumor recurrence. The tumor is more sensitive to radiation after receiving temozolomide in combination with radiation therapy. Temozolomide plus irradiation is more efficient than radiation alone. The most widely used kind of treatment is GBM surgery. Chemotherapy and radiation therapy come next. The rising use of targeted therapy to treat GBM is another factor that will likely cause the segment to expand. Due to growing research into creating novel, focused treatments for the condition, the market is predicted to expand.

Drug Class Analysis

The other segment, which accounted for 67% of revenue in 2021, had the largest revenue share. Everolimus, corticosteroids, and 5-aminolevulinic acids are further medications (5-ALA). In order to relieve symptoms and lessen vasogenic edema, corticosteroids might be utilized. Dexamethasone is the most often administered medication because it has no mineralocorticoid action. The potential to target the immune response for targeted therapy is highlighted by the immunosuppressive side effects of corticosteroids.

Bevacizumab, a targeted medicine for GBM treatment, has been authorized to treat GBM that has returned or that has just been discovered. The American FDA authorized bevacizumab in December 2017 for the treatment of GBM in adults. The drug is injected intravenously to halt blood vessel development and expansion. This will stop the formation of new blood vessels and slow the growth of the tumor. To manage GBM, the medication is used in conjunction with other treatments. Bevacizumab has continued to be shown to be effective in clinical investigations.

End-Use Analysis

The hospital sector accounted for 49.9% of the market in 2021 and is anticipated to keep that share throughout the forecast period. Hospitals are preferred by patients due to their accessibility to care and convenience. The rising number of GBM procedures and their complexity are anticipated to fuel market expansion. The segment for clinics will expand at the highest rate during the projection period. The market is expected to expand as noninvasive treatments like radiation therapy and tumor-treating field therapy become more widely used.

The rising use of noninvasive, patient-centered treatments including tumor-treating field therapy and external beam radiation therapy is attributed to promoting the growth of the segment. For example, Johns Hopkins Medicine provides tumor-treating field therapy, radiation therapy, and other treatments for brain cancer. The segment of ambulatory surgery centers will expand significantly during the projection period. Ambulatory surgery facilities may undertake more brain tumor resections in outpatient settings.

Key Market Segments

Treatment

• Surgery

• Targeted Therapy

• Radiation Therapy

• Chemotherapy

• Tumor Treating Field (TTF) Therapy

• Immunotherapy

Drug Class

• Temozolomide

• Lomustine

• Bevacizumab

• Carmustine Wafers

• Other Drug Classes

End-Use

• Hospitals

• Clinics

• Ambulatory Surgical Centers

Market Dynamics

Malignant tumors most frequently take the form of glioblastoma multifocal. It accounts for 16.8% of all primary head malignancies and about 55% of all gliomas. The prevalence of glioblastoma multifocal is higher in adults than in youngsters. With advancing age, so is the probability of getting glioblastoma multifocal. The market will be driven in the coming years by the rising acceptance of innovative therapies and combination therapies. In June 2019, the U.S. FDA approved Pfizer’s Zirabev as a biosimilar to Avastin for the treatment of recurrent glioblastoma and NSCLC.

In January 2020, the company introduced its product in the United States. The FDA authorized Samsung’s BLA for the SB8 bevacizumab candidate biosimilar in November 2019. As a result, the company will be able to launch more items in the next years. Tumor heterogeneity and variance in patient-to-patient care are predicted to be the main causes of the rise in demand for tailored therapy techniques to control glioblastoma multifocal. If new medicines are authorized, patients with glioblastoma multifocal illness will survive longer.

The FDA has given FDA investigational pharmaceuticals a unique status, which is anticipated to hasten the approval procedure and enable the commercialization of novel therapies. The FDA granted fast-track designation to Denovo Biopharma’s DB102 (enzastaurin) in July 2020 for the treatment of glioblastoma patients.

Regional Analysis

With a share of the global market of 44.2% in 2021, North America was the region with the highest representation. Government support for the healthcare industry, growing public awareness of rare diseases, accessibility to high-quality medical facilities, benevolent reimbursement policies, and significant government assistance are the main drivers influencing the regional market growth. With a growth rate of 10.8%, Asia Pacific will have the fastest growth. This is brought on by a number of things, such as the release of temozolomide generics, a stronger economy, an increase in the population of elderly people, and greater investments in the healthcare sector. The vast unmet market needs, growing awareness of GBM, and the presence of a strong pipeline are just a few of the drivers driving regional market growth (molecules that can bypass the blood-brain barrier).

Key Regions and Countries covered іn thе rероrt:

• North America

  • US

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Russia

  • Spain

  • Rest of Europe

• APAC

  • China

  • Japan

  • South Korea

  • India

  • Rest of Asia-Pacific

• South America

  • Brazil

  • Argentina

  • Rest of South America

• MEA

  • GCC

  • South Africa

  • Israel

  • Rest of MEA

Market Share Analysis

Major players in the GBM market are significantly spending on R&D to provide cutting-edge technology goods in order to obtain a competitive advantage. Major participants in the GBM treatment industry engage in licensing and partnership agreements, mergers and acquisitions, and licensing and partnership agreements in an effort to diversify their product offerings, improve their manufacturing capabilities, and gain a competitive advantage. For the treatment of glioblastoma multifocal, Lineage Cell Therapeutics and Immunomic Therapeutics agreed to a contract in April 2021 to develop the allogeneic vac immunotherapy platform. A US$ 2 million down payment and a total of US$ 67 million in milestone payments will be given to Lineage.

Key Market Players

• Merck & Co., Inc.

• Teva Pharmaceutical Industries Ltd.

• Amgen, Inc.

• Sun Pharmaceutical Industries Ltd.

• F. Hoffmann-La Roche Ltd.

• Pfizer Inc.

• Amgen, Inc.

• Arbor Pharmaceuticals, LLC

• Amneal Pharmaceuticals

• Other Key Players

For the Glioblastoma Multiforme Treatment Market research study, the following years have been considered to estimate the market size: